RF Ablation for Atrial Fibrillation
Trial Summary
What is the purpose of this trial?
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should be refractory or intolerant to at least one antiarrhythmic drug (AAD), which might imply changes to your current medication regimen.
What data supports the effectiveness of the treatment EPi-Sense Guided Coagulation System for atrial fibrillation?
Is RF Ablation for Atrial Fibrillation generally safe for humans?
How is the EPi-Sense Guided Coagulation System treatment for atrial fibrillation different from other treatments?
The EPi-Sense Guided Coagulation System is unique because it involves a minimally invasive surgical procedure that uses a suction support adapter to ensure effective contact between the ablation probe and the heart tissue, aiming for thorough coagulation. This approach is different from standard catheter-based ablation techniques and can be used as a stand-alone procedure or in combination with other cardiac surgeries.348910
Eligibility Criteria
This trial is for adults aged 18-79 with symptomatic long-standing persistent atrial fibrillation, who haven't responded to certain antiarrhythmic drugs. Participants must have a life expectancy over a year and a left atrium size ≤ 6.0 cm. Exclusions include pregnancy, severe heart failure, treatment for ventricular arrhythmias, recent participation in other trials, cognitive impairment affecting consent ability, and various medical conditions that could interfere with the study or are risks due to the procedure.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo the Hybrid Convergent procedure using the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation.
Follow-up
Participants are monitored for safety and effectiveness after the procedure, including evaluation of freedom from AF/AT/AFL and incidence of adverse events.
Long-term Follow-up
Participants' long-term outcomes are assessed, including quality of life and freedom from AF/AT/AFL over 3 years.
Treatment Details
Interventions
- EPi-Sense Guided Coagulation System
EPi-Sense Guided Coagulation System is already approved in United States for the following indications:
- Symptomatic long-standing persistent atrial fibrillation in patients who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
AtriCure, Inc.
Lead Sponsor